Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: Exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy

Breast Cancer Research and Treatment

Volumn 142, Issue 1, 2013, Pages 69-80

  Ohno, S ^a   Chow, L W C ^b   Sato, N ^c   Masuda, N ^d   Sasano, H ^e   Takahashi, F ^f   Bando, H ^g   Iwata, H ^h   Morimoto, T ⁱ   Kamigaki, S ^j   Nakayama, T ^j   Nakamura, S ^l   Kuroi, K ^m   Aogi, K ⁿ   Kashiwaba, M ^o   Yamashita, H ^p   Hisamatsu, K ^k   Ito, Y ^q   Yamamoto, Y ^r   Ueno, T ^s   Fakhrejahani, E ^s   Yoshida, N ^s   Toi, M ^s   more..

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

^b UNIMED Medical Institute   (Hong Kong)

^c NIIGATA CANCER CENTER HOSPITAL   (Japan)

^d OSAKA NATIONAL HOSPITAL   (Japan)

^e TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KITASATO UNIVERSITY   (Japan)

^g UNIVERSITY OF TSUKUBA   (Japan)

^h AICHI CANCER CENTER HOSPITAL   (Japan)

ⁱ Yao Municipal Hospital   (Japan)

^j Sakai City Medical Center   (Japan)

^k HIROSHIMA CITY ASA HOSPITAL   (Japan)

^l ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^m TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

ⁿ NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^o IWATE MEDICAL UNIVERSITY   (Japan)

^p NAGOYA CITY UNIVERSITY HOSPITAL   (Japan)

^q City of Nagoya   (Japan)

^r KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^s KYOTO UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

Breast cancer; Capecitabine; Docetaxel; Ki67; Neoadjuvant chemotherapy; Pathological complete response

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; HORMONE RECEPTOR; KI 67 ANTIGEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER STAGING; CONTROLLED STUDY; COUGHING; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PREOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUICIDE; VISUAL IMPAIRMENT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; PREOPERATIVE CARE; PROGNOSIS; RISK FACTORS; TAXOIDS; TREATMENT OUTCOME;

EID: 84888246639     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2691-y     Document Type: Article

References (27)

1. Wolmark N, Wang J, Mamounas E et al (2001) Preoperative chemotherapy in patients with operable breast cancer: 9-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30:96-102
2. Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26(5):778-785
3. Rouzier R, Perou C, Symmans W et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685
4. Nolen B, Marks KJ, Ta'san S et al (2008) Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res 10:R45
5. Fasching PA, Heusinger K, Haeberle L et al (2011) Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 11:486
6. Bear HD, Anderson S, Smith RE et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019-2027
7. Toi M, Nakamura S, Kuroi K et al (2008) Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat 110:531-539
8. Sawada N, Ishikawa T, Fukase Y et al (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4:1013-1019
9. Miwa M, Ura M, Nishida M et al (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274-1281
10. Blum JL, Jones SE, Buzdar AU et al (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485-493
11. Blum JL, Dieras V, Lo Russo PM et al (2001) Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92:1759-1768
12. Jinno H, Sakata M, Hayashida T et al (2010) A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/ cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer. Ann Oncol 21:1262-1266
13. Natoli C, Cianchetti E, Tinari N et al (2007) A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. Ann Oncol 18:1015-1020
14. Lebowitz PF, Eng-Wong J, Swain SM et al (2004) A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res 10:6764-6769
15. O'Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812-2823
16. Bouzubar N, Walker KJ, Griffiths K et al (1989) Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 59:943-947
17. Mikami Y, Ueno T, Yoshimura K, Tsuda H, Kurosimi M, Masuda S et al. (2013) Inter-observer concordance of Ki67 labeling index in breast cancer. Japan Breast Cancer Research Group (JBCRG) Ki67 Ring Study. Cancer Sci. doi: 10.1111/cas.12245
18. Stefanou D, Batistatou A, Nonni A, Arkoumani E, Agnantis NJ (2004) p63 expression in benign and malignant breast lesions. Histol Histopathol 19(2):465-471
19. Dewar R, Fadare O, Gilmore H, Gown AM (2011) Best practices in diagnostic immunohistochemistry: myoepithelial markers in breast pathology. Arch Pathol Lab Med 135(4):422-429
20. Werling RW, Hwang H, Yaziji H, Gown AM (2003) Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain. Am J Surg Pathol 27(1):82-90
21. von Minckwitz G, Rezai M, Loibl S et al (2010) Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro Study. J Clin Oncol 28(12):2015-2023
22. Leonard R, O'Shaughnessy J, Vukelja S et al (2006) Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? Ann Oncol 17:1379-1385
23. Caudle AS, Ganzalez-Angulo AM, Hunt KL et al (2010) Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(11):1821-1828
24. Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E et al (2012) Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 48(18):3342-3354
25. Yerushalmi R, Woods R, Ravdin PM et al (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11:174-183
26. Zhang GC, Qian XK, Guo ZB et al (2012) Pre-treatment hormal receptor status and Ki67 index predict pathological complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients. Med Oncol 29(5):3222-3231
27. Luporsi E, Andre F, Spyratos F et al (2012) Ki-67: level of evidence and methodoligical considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 132(3):895-915